Dormant Cells: The Original Cause of Tumor Recurrence and Metastasis

详细信息    查看全文

• 作者：Jie Li ; Enze Jiang ; Xinxing Wang ; Anna Junjie Shangguan…
• 关键词：Dormant cells ; Tumor ; Metastasis ; Tumor recurrence ; Cell cycle
• 刊名：Cell Biochemistry and Biophysics
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：72
• 期：2
• 页码：317-320
• 全文大小：392 KB
• 参考文献：1.Felsher, D. W. (2008). Tumor dormancy and oncogene addiction. APMIS, 116(7鈥?), 629鈥?37.PubMed View Article
  2.Weinberg, R. A. (2008). The many faces of tumor dormancy. APMIS, 116(7鈥?), 548鈥?51.PubMed View Article
  3.Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834鈥?46.PubMed Central PubMed View Article
  4.Logan, P. T., Fernandes, B. F., Di Cesare, S., Marshall, J. C., Maloney, S. C., & Burnier, M. N., Jr. (2008). Single-cell tumor dormancy model of uveal melanoma. Clinical and Experimental Metastasis, 25(5), 509鈥?16.PubMed View Article
  5.Peeters, C. F., de Waal, R. M., Wobbes, T., & Ruers, T. J. (2008). Metastatic dormancy imposed by the primary tumor: Does it exist in humans? Annals of Surgical Oncology, 15(11), 3308鈥?315.PubMed View Article
  6.Allgayer, H., & Aguirre-Ghiso, J. A. (2008). The urokinase receptor (U-Par)鈥攁 link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS, 116(7鈥?), 602鈥?14.PubMed Central PubMed View Article
  7.Udagawa, T. (2008). Tumor dormancy of primary and secondary cancers. APMIS, 116(7鈥?), 615鈥?28.PubMed View Article
  8.Naumov, G. N., MacDonald, I. C., Weinmeister, P. M., Kerkvliet, N., Nadkarni, K. V., Wilson, S. M., et al. (2002). Persistence of solitary mammary carcinoma cells in a secondary site: A possible contributor to dormancy. Cancer Research, 62(7), 2162鈥?168.PubMed
  9.McDougall, S. R., Anderson, A. R., & Chaplain, M. A. (2006). Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: Clinical implications and therapeutic targeting strategies. Journal of Theoretical Biology, 241(3), 564鈥?89.PubMed View Article
  10.Naumov, G. N., Folkman, J., Straume, O., & Akslen, L. A. (2008). Tumor-vascular interactions and tumor dormancy. APMIS, 116(7鈥?), 569鈥?85.PubMed View Article
  11.Kang, S. Y., & Watnick, R. S. (2008). Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and Vegf expression. APMIS, 116(7鈥?), 638鈥?47.PubMed View Article
  12.Naumov, G. N., Folkman, J., & Straume, O. (2009). Tumor dormancy due to failure of angiogenesis: Role of the microenvironment. Clinical and Experimental Metastasis, 26(1), 51鈥?0.PubMed View Article
  13.Bagri, A., Berry, L., Gunter, B., Singh, M., Kasman, I., Damico, L. A., et al. (2010). Effects of anti-Vegf treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clinical Cancer Research, 16(15), 3887鈥?900.PubMed View Article
  14.Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology, 3(11), 991鈥?98.PubMed View Article
  15.Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450(7171), 903鈥?07.PubMed View Article
  16.Waldhauer, I., & Steinle, A. (2008). Nk cells and cancer immunosurveillance. Oncogene, 27(45), 5932鈥?943.PubMed View Article
  17.Quesnel, B. (2008). Tumor dormancy and immunoescape. APMIS, 116(7鈥?), 685鈥?94.PubMed View Article
  18.Muller-Hermelink, N., Braumuller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., et al. (2008). Tnfr1 signaling and Ifn-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell, 13(6), 507鈥?18.PubMed View Article
  19.Paez, D., Labonte, M. J., Bohanes, P., Zhang, W., Benhanim, L., Ning, Y., et al. (2012). Cancer dormancy: A model of early dissemination and late cancer recurrence. Clinical Cancer Research, 18(3), 645鈥?53.PubMed View Article
  20.Correa, R. J., Peart, T., Valdes, Y. R., DiMattia, G. E., & Shepherd, T. G. (2012). Modulation of Akt activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis, 33(1), 49鈥?8.PubMed View Article
  21.Favaro, E., Amadori, A., & Indraccolo, S. (2008). Cellular interactions in the vascular niche: Implications in the regulation of tumor dormancy. APMIS, 116(7鈥?), 648鈥?59.PubMed View Article
  22.Ranganathan, A. C., Adam, A. P., & Aguirre-Ghiso, J. A. (2006). Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle, 5(16), 1799鈥?807.PubMed Central PubMed View Article
  23.Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K., & Ossowski, L. (2001). Urokinase receptor and fibronectin regulate the Erk(Mapk) to P38(Mapk) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Molecular Biology of the Cell, 12(4), 863鈥?79.PubMed Central PubMed View Article
  24.Barkan, D., Kleinman, H., Simmons, J. L., Asmussen, H., Kamaraju, A. K., Hoenorhoff, M. J., et al. (2008). Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research, 68(15), 6241鈥?250.PubMed Central PubMed View Article
  25.Barkan, D., El Touny, L. H., Michalowski, A. M., Smith, J. A., Chu, I., Davis, A. S., et al. (2010). Metastatic growth from dormant cells induced by a Col-I-enriched fibrotic environment. Cancer Research, 70(14), 5706鈥?716.PubMed Central PubMed View Article
  26.Goulet, B., Chan, G., Chambers, A. F., & Lewis, J. D. (2012). An emerging role for the nuclear localization of Maspin in the suppression of tumor progression and metastasis. Biochemistry and Cell Biology, 90(1), 22鈥?8.PubMed
  27.Badve, S., & Nakshatri, H. (2012). Breast-cancer stem cells-beyond semantics. Lancet Oncology, 13(1), e43鈥揺48.View Article
  28.Goss, P., Allan, A. L., Rodenhiser, D. I., Foster, P. J., & Chambers, A. F. (2008). New clinical and experimental approaches for studying tumor dormancy: Does tumor dormancy offer a therapeutic target. APMIS, 116(7鈥?), 552鈥?68.PubMed View Article
  29.Rameshwar, Pranela. (2012). Would cancer stem cells affect the future investment in stem cell therapy. World Journal of Experimental Medicine, 2(2), 26.PubMed Central PubMed View Article
  30.Uhr, J. W., & Pantel, K. (2011). Controversies in clinical cancer dormancy. Proceedings of the National Academy of Sciences, 108(30), 12396鈥?2400.View Article
  
• 作者单位：Jie Li (1)
  Enze Jiang (2)
  Xinxing Wang (1)
  Anna Junjie Shangguan (3)
  Luo Zhang (4)
  Zhenghong Yu (5)
  
  1. Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China
  2. Nanjing University School of Medicine, Nanjing, China
  3. Weinberg College of Arts and Sciences at Northwestern University, Evanston, IL, USA
  4. Changzhou TCM Hospital, Changzhou, China
  5. Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China
  
• 刊物主题：Biochemistry, general; Pharmacology/Toxicology; Biotechnology; Cell Biology; Biophysics and Biological Physics;
• 出版者：Springer US
• ISSN：1559-0283

文摘

Tumor dormancy is one of the stages in tumor development without clinical symptoms. Tumor dormant cells may appear in early stages of tumor development, as well as in micrometastasis and minimal residual disease. The mechanism for the switch of dormant cells between quiescent and proliferative stages is still largely unknown. Potential mechanisms that may account for the transition between dormant tumor cells and proliferative cells include angiogenesis, immune response, cellular factors, and signaling pathways. The clinical and therapeutic importance of dormant cells requires further studies to provide therapeutic strategies for inhibition of metastasis and tumor recurrence.